WEBINAR | Clinical Signals and Strategic Shifts in Oncology
Oncology drug development is entering a new phase—marked by innovation in immuno-oncology, next-generation antibody-drug conjugates (ADCs) and biomarker-guided approaches. With the 2025 European Society for Medical Oncology (ESMO) annual meeting as a backdrop, this webinar brings together expert perspectives on the emerging science, signals and strategies driving the future of cancer care.
What treatment modalities are gaining traction among oncologists—and why? How is clinical data translating into strategic shifts in development, trial design and commercialization? Our panel of experts unpacks findings from ESMO and explores what it means for biopharma leaders aiming to differentiate assets and accelerate development.
In this webinar, you will learn:
- How new data unveiled at ESMO 2025 may influence the future of cancer treatment, including shifts in clinical practice and strategic priorities
- The current landscape of antibody-drug conjugates (ADCs) and what’s needed to advance the next generation into first-in-human trials
- The latest developments in immuno-oncology, including how emerging therapies are delivering longer-lasting responses and reshaping the standard of care
- Which treatment modalities and research are capturing oncologists’ attention and how these breakthroughs are opening new pathways for market differentiation and commercial success
Watch now to gain firsthand insights into what’s reshaping standards of care and unlocking new competitive opportunities in oncology.
Related Content
Looking for exclusive insight?
